MI-CRE 2023 Research Symposium and Policy Forum - Abstracts

Click on the abstract title to open the abstract in a new window.

• Prevalence of smoking cessation pharmacotherapy use during pregnancy: a multi-national population-based study

AL Robijn, UNSW Sydney; DT Tran; JM Cohen; S Donald; CE Cesta; K Furu; L Parkin; SA Pearson; J Reutfors; H Zoega; N Zwar; A Havard.

•  The risk of congenital malformations in infants exposed in the first trimester to smoking cessation pharmacotherapies: A multi-national cohort study
  

DT Tran, UNSW Sydney; JM Cohen;  S Donald; AL Robijn; CE Cesta ; K Furu; L Parkin;S Pearson; J Reutfors; H Zoega; N Zwar; A Havard.

• Opioid analgesic exposure during the first trimester of pregnancy and the risk of major congenital malformations in infants: a systematic review and meta-analysis

B Varney, UNSW Sydney; J Brett; H Zoega; M Powell; M Gillies; SA Pearson; A Havard.

• Antipsychotic use during pregnancy and risk of poor academic performance in children: A multinational cohort study

C Bruno, UNSW Sydney; C Cesta; V Hjellvik; SU Pilgaard; M Bjørk; B Öztürk Esen; M Gillies; M Gissler; A Havard; Ø Karlstad; M Leinonen; M Nørgaard; SA Pearson; J Reutfors; K Furu; J Cohen; H Zoega.

• National trends in the use of medicines for opioid agonist treatment, 2013-2022

C Bharat; K Chidwick, UNSW Sydney; N Gisev; M Farrell; R Ali; L Degenhardt.

• Initiation and long-term use of opioids after hospitalisation or emergency department presentation

M Gillies, UNSW Sydney; K Chidwick; C Bharat; X Camacho; D Currow; N Gisev; L Degenhardt; SA Pearson.

• The risk of fatal opioid overdose associated with the concurrent use of opioid analgesics and psychotropic medicines: a retrospective population-based cohort study

N Gisev, UNSW Sydney; L Buizen; C Bharat; R Hopkins; S Larney; D Currow; A Dunlop; A Wilson; FM Blyth; T Dobbins; SA Pearson; L Degenhardt.

• Beyond the label: Real-world evidence of antipsychotic utilization in Australia (2000–2021) using two medication datasets

RP Radha Krishnan, University of Sydney; C Harrison; J Raubenheimer; N Buckley.

• Expanded access to publicly subsidised lisdexamfetamine treatment for adults with attention-deficit/ hyperactivity disorder: an interrupted time series analysis

C Bruno, UNSW Sydney; H Zoega; M Gillies; A Havard; D Coghill; SA Pearson; J Brett.

Click on the abstract title to open the abstract in a new window.

• Cardiovascular medicine use in adults with ADHD: a nationwide study in Australia

M Araki, UNSW Sydney; H Zoega; M Gillies; J de Oliveira Costa.

• Patterns and timing of add-on anti-hyperglycaemic medicines after initiating metformin

TY Milder, UNSW Sydney; J Lin; SA Pearson;  JR Greenfield; R Day; SL Stocker; MO Falster; J de Oliveira Costa.

• Paracetamol dose and hospitalisation for chronic obstructive pulmonary disease exacerbation: the case for lowering the starting dose

L Kelly, University of South Australia; N Pratt; T Laba.

• Population Effect of Medicare-Funded Chronic Disease Management Policies on Medication Adherence Trajectories After Stroke: A Sub-Study of the PRECISE Emulated Target Trial

LL Dalli, Monash; NE Andrew; MT Olaiya; D Ung; J Kim; L Churilov; DA Cadilhac; V Sundararajan; AG Thrift; MR Nelson; NA Lannin; R Barnden; V Srikanth; MF Kilkenny.

• What “proof” is in the pudding? Integrating methodologies for adverse event signal detection

J Janetzki, University of South Australia; Ml Ward; M Sykes; NL Pratt.

• Burden of biologic medicines in the Australian population

KM Duszynski,University of South Australia; KA Hall; JB Hillen; TE Stanford; EE Roughead; MB Ward; LM Kalisch Ellett; NL Pratt.

• Visualised dispensing: An interactive app to monitor biologic medicine dispensing in Australia

KA Hall, University of South Australia; KM Duszynski; JB Hillen; TE Stanford; NL Pratt.

• The impact of biosimilars on biologic medicines market in Australia: Medicines policy in action

JB Hillen, University of South Australia; T Stanford; M Ward; K Duszynski; NL Pratt.

• Uptake and Australian cohort characteristics for innovative migraine prophylactic medicines

JN Ho, University of South Australia; KA Hall; JB Hillen; J Janetzki; M Ward; B Daniels; NL Pratt.